Rubius Therapeutics to Present at the Virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conference in February 2022
February 01 2022 - 8:00AM
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage
biopharmaceutical company that is biologically engineering red
blood cells to create an entirely new class of cellular medicines
called Red Cell Therapeutics™ for the treatment of cancer and
autoimmune diseases, today announced that the executive management
team will present and host meetings with investors at the virtual
Guggenheim Healthcare Talks and SVB Leerink Global Healthcare
Conference in February.
Pablo J. Cagnoni, M.D., president and chief executive officer,
will provide a corporate update through fireside chats at
Guggenheim Healthcare Talks | Idea Forum | Oncology Day on February
10, 2022, 08:00 a.m. EST and at the 11th Annual SVB Leerink Global
Healthcare Conference on February 18, 2022, 1:00 p.m. EST. Live
audio webcasts for these events will be available within the
Investors & Media section of the Rubius Therapeutics website.
Archived replays will be accessible for 90 days following the
events.
About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical
company developing a new class of medicines called Red Cell
Therapeutics™. The Company’s proprietary RED PLATFORM® was designed
to biologically engineer and culture Red Cell Therapeutics™ that
are selective, potent and off-the-shelf allogeneic cellular
therapies for the potential treatment of several diseases across
multiple therapeutic areas. Rubius’ initial focus is to advance
RCT™ product candidates for the treatment of cancer and autoimmune
diseases by leveraging two distinct therapeutic modalities — potent
cell-cell interaction and tolerance induction.
Rubius Therapeutics was recently named among the 2021 Top
Places to Work in Massachusetts by the Boston Globe, and its
manufacturing site was recently named 2021 Best Places to
Work in Rhode Island by Providence Business News. For more
information, visit www.rubiustx.com, follow us on Twitter or
LinkedIn or like us on Facebook.
Contacts:InvestorsElhan Webb,
CFA, VP Investor Relationselhan.webb@rubiustx.com
MediaMarissa Hanify, Director, Corporate
Communicationsmarissa.hanify@rubiustx.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Sep 2023 to Sep 2024